Compare MX & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MX | RANI |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.6M | 120.0M |
| IPO Year | N/A | 2021 |
| Metric | MX | RANI |
|---|---|---|
| Price | $3.09 | $1.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $5.75 | ★ $8.67 |
| AVG Volume (30 Days) | 309.8K | ★ 1.2M |
| Earning Date | 03-11-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $224,755,000.00 | $1,200,000.00 |
| Revenue This Year | N/A | $414.59 |
| Revenue Next Year | N/A | $30.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.62 | N/A |
| 52 Week Low | $2.18 | $0.39 |
| 52 Week High | $5.16 | $3.87 |
| Indicator | MX | RANI |
|---|---|---|
| Relative Strength Index (RSI) | 49.93 | 29.86 |
| Support Level | $2.78 | $1.07 |
| Resistance Level | $2.98 | $1.26 |
| Average True Range (ATR) | 0.13 | 0.06 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 19.79 | 13.70 |
MagnaChip Semiconductor Corp designs and manufactures analog and mixed-signal semiconductor platform solutions for communications, Internet of Things applications, consumer, industrial and automotive applications. The company's product portfolio consists of large display solutions, mobile display solutions, sensor solutions, LED solutions, mobile solutions, and power conversions. The company operates in two segments namely, Transitional Fab 3 foundry services and Standard products business. The company operates in Korea, Asia Pacific (other than Korea), United States and Europe.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.